Published • loading... • Updated
Hundreds of deaths suspected of being linked to weight-loss jabs reported to regulator
The regulator said the reports cover more than 158,000 adverse reactions, while stressing they do not prove the medicines caused the deaths.
- Health officials have received reports of more than 200 deaths suspected of being linked to weight-loss jabs, according to figures from the Medicines and Healthcare Products Regulatory Agency .
- Patients and medical professionals submit these reports through the MHRA Yellow Card scheme, designed to flag potential safety signals for medications including Wegovy, Mounjaro, and Saxenda.
- Mounjaro recorded more than 100,000 complaints and 98 fatal outcomes, while semaglutide and liraglutide each reported 37 fatal outcomes, according to Yellow Card data.
- Experts caution against interpreting raw figures as proof of harm, while manufacturers Eli Lilly and Novo Nordisk stated they actively monitor safety information for all medicines.
- Clinical trials show GLP-1 medications reduced major cardiovascular events by 20% compared to placebos, demonstrating that for many patients the benefits outweigh potential side effects.
Insights by Ground AI
18 Articles
18 Articles
Weight loss jabs linked to more than 200 deaths, regulator warns
Figures submitted to Britain's medicines regulator have revealed that more than 200 deaths with suspected links to popular weight-loss injections have been flagged by members of the public and healthcare professionals.The data, drawn from the Medicines and Healthcare Products Regulatory Agency's Yellow Card Scheme, also show upwards of 158,000 reported adverse reactions connected to the medications.The Yellow Card system allows anyone who suspec…
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources18
Leaning Left3Leaning Right4Center5Last UpdatedBias Distribution42% Center
Bias Distribution
- 42% of the sources are Center
42% Center
L 25%
C 42%
R 33%
Factuality
To view factuality data please Upgrade to Premium
